Telehealth Advocates Challenge FDA to Measure AI Medical Devices Against Real-World Care Gaps, Not Perfect Clinics
ATA Action urges regulators to compare AI tools to actual alternatives in underserved areas—often six-month waits or no care at all—while proposing a federal-state sandbox to prevent jurisdictional chaos.
Illustration: AI-generated
The American Telemedicine Association's advocacy arm is pushing the FDA to fundamentally rethink how it evaluates AI-powered medical devices, arguing that regulators should measure these tools against the realities of healthcare access rather than idealized clinical scenarios unavailable to millions of Americans.
In formal comments submitted to FDA Docket No. FDA-2026-N-7874, ATA Action endorsed the agency's proposed two-axis risk framework for generative AI medical devices while urging a critical shift in perspective: compare AI performance not to perfect physician visits, but to what patients actually face in underserved areas—often six-month wait times or no care whatsoever.
A Risk Framework Grounded in Clinical Reality
The FDA's discussion paper proposes evaluating AI medical devices along two dimensions: the clinical autonomy of the software and the potential severity of harm from erroneous outputs. ATA Action supports this approach but argues the agency must anchor risk assessment in real-world care alternatives.
"The baseline for comparison shouldn't be an immediate appointment with a specialist," explained Joe Nye, Head of Federal Government Relations for ATA Action. "In rural America, that baseline is often a six-month wait or driving three hours each way—if care is available at all."
The comments, addressed to Dr. Michelle Tarver, Director of FDA's Center for Devices and Radiological Health, emphasize that regulation should focus on clinical function and risk rather than the underlying AI technology itself. This function-based approach would allow developers to avoid unnecessary pre-market clearance for low-risk administrative or informational features while maintaining rigorous oversight for high-risk autonomous functions.
Validation Across Underrepresented Populations
ATA Action recommends mandatory testing requirements that reflect America's demographic diversity. AI medical devices should undergo validation across rural populations, patients with limited health literacy, and non-English speakers—groups historically underrepresented in clinical trials and vulnerable to algorithmic bias.
This real-world validation standard acknowledges that for many patients, AI-assisted triage and screening tools may deliver clinically superior outcomes compared to prolonged care delays or complete absence of access in shortage areas.
A Regulatory Sandbox to Prevent State-by-State Fragmentation
ATA Action proposes a federal-state clinical AI sandbox modeled on the FDA's TEMPO pilot (Technology-Enabled Meaningful Patient Outcomes). This regulatory testing ground would allow controlled deployment of AI tools without triggering state-by-state jurisdictional conflicts that could fragment the market and delay access.
The proposal reflects growing concern that without coordinated oversight, healthcare AI companies could face a patchwork of conflicting state regulations, particularly as these tools increasingly cross traditional boundaries between medical devices, clinical decision support, and general wellness applications.
ATA Action also requested formal FDA coordination with the Centers for Medicare & Medicaid Services to establish clear coverage pathways, recognizing that regulatory clearance means little if reimbursement remains uncertain.
Implications for Underserved Areas
The comments arrive as healthcare AI companies navigate evolving guidance, including the FDA's January 2026 clinical decision support and general wellness documents. For clinicians in rural and underserved areas, the proposed framework could enable deployment of AI-assisted tools without regulatory paralysis, potentially reducing patient wait times from months to immediate access.
The underlying question is whether regulators will measure innovation against theoretical perfection or practical alternatives—a choice with implications for the 60 million Americans living in health professional shortage areas.
Sources
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.